Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Humoral Immune Responses

Humoral Immune Responses

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Jaundice

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Seventh Åland Island Meeting on von Willebrand Disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2026

Same author

Von Willebrand disease.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026

Same author

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026

Same author

The landmark contribution by Erik von Willebrand.

Haematologica·2026

Same author

Evaluation of kidney function and damage in patients with hemophilia B-insights from the B-Natural study.

Research and practice in thrombosis and haemostasis·2025

Same author

Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotype.

HemaSphere·2025

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Quantification of Humic and Fulvic Acids in Humate Ores, DOC, Humified Materials and Humic Substance-Containing Commercial Products

Quantification of Humic and Fulvic Acids in Humate Ores, DOC, Humified Materials and Humic Substance-Containing Commercial Products

Published on: March 18, 2022

Haemate P/Humate-P: a systematic review.

Erik Berntorp¹

¹Malmö Centre for Thrombosis and Haemostasis, Malmö University Hospital, Sweden. erik.berntorp@med.lu.se

Thrombosis Research

|December 1, 2009

Summary

Haemate P, a pasteurized plasma concentrate, offers safe and effective treatment for von Willebrand disease (VWD) and hemophilia A. With over 25 years of clinical use, it demonstrates predictable pharmacokinetics and a strong safety profile.

Area of Science:

Hematology
Plasma-derived therapeutics

Background:

Haemate P/Humate-P, developed in the 1970s, was the first pasteurized plasma-derived concentrate containing von Willebrand factor (VWF) and factor VIII (FVIII).
It was approved in Germany in 1981 and is now available in over 35 countries.

Purpose of the Study:

To review the clinical experience and efficacy of Haemate P in treating von Willebrand disease (VWD) and hemophilia A.
To highlight its safety profile and role in replacement therapy.

Main Methods:

Review of extensive clinical data and published literature spanning over 25 years.
Analysis of pharmacokinetic predictability, hemostatic efficacy, and safety in pediatric and adult patients.

Main Results:

Haemate P demonstrates predictable pharmacokinetics and consistent hemostatic efficacy.

More Related Videos

Measurement of Heme Synthesis Levels in Mammalian Cells

Measurement of Heme Synthesis Levels in Mammalian Cells

Published on: July 9, 2015

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

Published on: January 19, 2024

Related Experiment Videos

Last Updated: Jun 18, 2026

Quantification of Humic and Fulvic Acids in Humate Ores, DOC, Humified Materials and Humic Substance-Containing Commercial Products

Quantification of Humic and Fulvic Acids in Humate Ores, DOC, Humified Materials and Humic Substance-Containing Commercial Products

Published on: March 18, 2022

Measurement of Heme Synthesis Levels in Mammalian Cells

Measurement of Heme Synthesis Levels in Mammalian Cells

Published on: July 9, 2015

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

Published on: January 19, 2024

It possesses a favorable safety profile with rare adverse events and a very low incidence of thromboembolic events.

VWF composition is similar to normal plasma, with minimized virus transmission risk.

Conclusions:

Haemate P is a well-established, safe, and effective treatment for VWD and hemophilia A.
Its extensive clinical experience has established it as the gold standard for VWD replacement therapy.
Ongoing research explores its potential in other applications, such as immune tolerance induction therapy for hemophilia A.